Polycystic ovary syndrome (PCOS) has a new proposed name: what does it mean for patients?

For many years, women diagnosed with polycystic ovary syndrome, known as PCOS, have often been left with more questions than answers. Does it mean I have cysts? Is it only about irregular periods? Is it mainly a fertility problem? Does it affect my metabolism too?

These questions are understandable, because the name itself has never fully explained what this condition really is.

A recent publication in The Lancet proposes a new name for PCOS: Polyendocrine Metabolic Ovarian Syndrome, or PMOS. In Spanish, this could be translated as síndrome ovárico metabólico poliendocrino, with the possible acronym SOMP. The proposal is the result of a broad international consensus process involving patients, healthcare professionals and scientific organisations from different regions of the world.

Why is the name changing?

The main reason is accuracy.

The term “polycystic ovary syndrome” suggests that the condition is mainly defined by ovarian cysts. However, this is misleading. In many patients, what is seen on ultrasound is not pathological cysts, but multiple small follicles that have not developed in the usual way.

This distinction matters. When the name focuses on “cysts”, patients may believe the condition is only located in the ovaries. In reality, PCOS is much broader. It can involve hormonal, metabolic, ovulatory, dermatological, psychological and reproductive features.

The new proposed name, PMOS, aims to describe the condition more accurately and avoid reducing it to an ovarian or fertility-only issue.

One of the most common hormonal conditions

PCOS is one of the most common endocrine conditions in women of reproductive age. According to the article, it affects more than 170 million women worldwide.

Despite being so common, many women experience delayed diagnosis, fragmented care or incomplete explanations about what is happening in their body. Some are told to come back when they want to get pregnant. Others are treated only for acne, irregular periods or weight changes, without a complete view of the condition.

This is one of the reasons why the name change is important: it encourages a broader medical perspective.

What does PMOS mean?

The new proposed name is Polyendocrine Metabolic Ovarian Syndrome.

Each word has a specific meaning:

Polyendocrine means that several hormonal systems may be involved. PCOS/PMOS is not only about the ovaries. It can involve androgens, insulin, neuroendocrine hormones and other hormonal mechanisms that influence the menstrual cycle, ovulation, skin, metabolism and fertility.

Metabolic recognises a central part of the condition. Many patients may have insulin resistance or a higher risk of metabolic changes, such as altered glucose levels, type 2 diabetes, dyslipidaemia, hypertension or long-term cardiometabolic risk.

Ovarian keeps the reference to the ovaries, because ovarian function is still relevant. Many patients experience irregular ovulation, long menstrual cycles, absent periods or fertility difficulties. However, the new name avoids the misleading idea that “cysts” are the defining feature.

In other words, PMOS does not describe a new disease. It describes the same condition more precisely.

Who decided this change?

This proposal was not made by one doctor, one clinic or one organisation. It comes from a structured global consensus process.

The publication describes engagement with patients, multidisciplinary healthcare professionals and organisations across world regions. The process included surveys, workshops, implementation analysis and communication review. The aim was to find a name that was medically accurate, easy to communicate, culturally appropriate, less stigmatising and feasible to implement in clinical practice and research.

This discussion has been ongoing for years. In 2012, the National Institutes of Health (NIH) had already highlighted that the name PCOS was misleading and recommended considering a more accurate name.

What are the benefits for patients?

A better name can help patients receive better explanations.

For someone experiencing irregular cycles, acne, excess hair growth, difficulty losing weight or trouble conceiving, the new term can make it clearer that these symptoms may be connected. They are not isolated problems. They may be part of a wider hormonal and metabolic condition.

The name PMOS also supports a more complete medical approach. Fertility is important, but it is not the only aspect. Patients may also need assessment of ovulation, androgen levels, insulin resistance, metabolic health, emotional wellbeing and long-term risks.

For patients, this can mean earlier diagnosis, more personalised care and less confusion.

Will diagnosis or treatment change?

The name change does not automatically change diagnosis or treatment.

Patients who have already been diagnosed with PCOS do not suddenly have a different condition. What changes is the way the condition is named and understood.

In clinical practice, both names are likely to coexist for some time: PCOS and PMOS. The publication proposes a managed transition period, with updates to educational materials, medical terminology, healthcare systems, research databases and international classification systems.

What should remain central is personalised care. Not all patients with PCOS/PMOS have the same symptoms or the same priorities. Some need support with menstrual cycles. Others are mainly concerned about fertility, metabolic health, skin symptoms or emotional wellbeing.

A change of name, and a change of perspective

The most important message is that this change should not create fear. It should create clarity.

The old name placed too much attention on the ovaries and on “cysts”. The new proposed name helps explain that this is a common, complex and varied condition involving hormones, metabolism and ovarian function.

At Tambre, we believe this broader perspective is especially important for patients. Understanding what is happening in your body can help you ask better questions, seek care earlier and make informed decisions about your health and fertility.

PCOS has not disappeared. It has been renamed to better reflect what science already knows: this condition is not only about ovaries. It deserves a complete, personalised and evidence-based approach.

Frequently asked questions about the proposed name change from PCOS to PMOS

Polycystic ovary syndrome, known as PCOS in English and SOP in Spanish, may now be referred to as Polyendocrine Metabolic Ovarian Syndrome, or PMOS. This proposed change aims to describe the condition more accurately: not only as an ovarian issue, but as a broader hormonal and metabolic condition.

Who decided this name change?

The proposed change did not come from one person, one clinic or one organisation. It was developed through a broad international consensus process published in The Lancet.

Patients, healthcare professionals from different specialties and scientific organisations from several world regions took part in the process. The aim was to assess whether the name polycystic ovary syndrome still accurately described the condition.

After global surveys, consensus workshops and implementation analysis, the proposed new name is Polyendocrine Metabolic Ovarian Syndrome, or PMOS.

What are the old and new acronyms in English and Spanish?

Until now, the condition has been known in English as PCOS, which stands for Polycystic Ovary Syndrome. In Spanish, it is known as SOP, from síndrome de ovario poliquístico.

Previous name in English: Polycystic Ovary Syndrome.

Previous acronym in English: PCOS.

Previous name in Spanish: síndrome de ovario poliquístico.

Previous acronym in Spanish: SOP.

The proposed new name in English is Polyendocrine Metabolic Ovarian Syndrome, with the acronym PMOS.

In Spanish, the most accurate translation would be síndrome ovárico metabólico poliendocrino. Following the natural order of the Spanish expression, the possible acronym would be SOMP.

In summary: in English, the proposed new acronym is PMOS. In Spanish, it can be explained as síndrome ovárico metabólico poliendocrino, with the possible acronym SOMP.

Why is the name changing?

The current name can be misleading. The word “polycystic” suggests that the condition is defined by cysts in the ovaries, but these are not pathological cysts in the usual sense.

PCOS is much broader. It can involve hormonal, metabolic, ovulatory, dermatological, psychological and reproductive features. The new proposed name aims to reflect what is really happening in the body more accurately.

What does PMOS mean?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome.

• Polyendocrine: several hormones and endocrine mechanisms may be involved.
• Metabolic: the condition can be associated with insulin resistance, altered glucose metabolism, cardiometabolic risk and other metabolic changes.
• Ovarian: ovarian function remains important, especially in relation to ovulation, menstrual cycles and fertility.

Does this mean I no longer have PCOS?

Not exactly. If you have already been diagnosed with PCOS, this name change does not mean your diagnosis disappears or that you now have a different condition.

What changes is the way the condition is named. The new term is intended to describe it more accurately and avoid a narrow focus on the ovaries or on “cysts”.

For some time, both names are likely to be used: PCOS and PMOS. In Spanish, the previous acronym SOP may also coexist with the possible new acronym SOMP.

Is PCOS only a fertility problem?

No. Although many patients discover they have PCOS when they are trying to conceive, this condition is not only related to fertility.

It may affect menstrual cycles, ovulation, skin, metabolism, weight, insulin resistance, risk of type 2 diabetes, cardiovascular health and emotional wellbeing.

This is why the new name is important: it helps patients and professionals understand that the condition should be approached in a more complete way.

Will the name change modify my treatment?

The name change does not automatically modify treatment. What matters most is an individual medical assessment.

Not all patients have the same symptoms or the same needs. Some may consult because of irregular periods, others because of acne or excess hair growth, others because of metabolic changes, and others because they are having difficulty getting pregnant.

Treatment should always be adapted to each patient’s clinical situation, health goals and stage of life.

Why can this change be positive for patients?

Because a more accurate name can help patients better understand the condition. Many women have experienced years of uncertainty, delayed diagnosis or incomplete explanations about their symptoms.

A better name may support earlier diagnosis, clearer medical education and more complete follow-up. It may also reduce stigma and help patients understand that the condition is not simply about “having cysts on the ovaries”.

Naming a condition accurately can also help improve the way it is understood and treated.

Do I need to do anything if I was diagnosed with PCOS?

You do not need to feel alarmed by the proposed name change. If you already have a PCOS diagnosis, the most useful step is to review with your specialist whether your care includes all relevant aspects of the condition: hormonal, metabolic, ovarian, dermatological, emotional and reproductive.

This is especially important if you have irregular cycles, signs of hyperandrogenism, insulin resistance or if you are trying to conceive. A personalised medical assessment can help you make better decisions.

How can PCOS or PMOS affect fertility?

PCOS, or PMOS according to the proposed new name, can affect fertility mainly because it may alter ovulation. Some women ovulate irregularly or have very long cycles, which can make it more difficult to identify fertile days or achieve pregnancy naturally.

However, having PCOS or PMOS does not necessarily mean you cannot become a mother. With the right diagnosis and a personalised treatment plan, many patients achieve pregnancy.

The key is to study each case carefully, assessing ovulation, ovarian reserve, metabolic health and any other factors that may influence fertility.

What is the main message for patients?

The main message is that this change should bring clarity, not concern. The old name did not fully reflect the complexity of the condition. The new proposed name aims to describe a common, complex and diverse syndrome more accurately.

PCOS, now proposed as PMOS, is not only an ovarian issue. It is a hormonal, metabolic and ovarian condition that deserves complete, personalised and evidence-based care.